Tatsunori Hanai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1340027/publications.pdf Version: 2024-02-01



Τατειινορι Ηανιαι

#	Article	IF	CITATIONS
1	Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis. Journal of Parenteral and Enteral Nutrition, 2022, 46, 858-866.	1.3	20
2	Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liverâ€related complications. Hepatology Research, 2022, 52, 364-370.	1.8	7
3	Survival benefit of Lâ€carnitine supplementation in patients with cirrhosis. Journal of Parenteral and Enteral Nutrition, 2022, , .	1.3	2
4	Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy. Hepatology Research, 2021, 51, 662-673.	1.8	21
5	Increased Visceral Adipose Tissue and Hyperinsulinemia Raise the Risk for Recurrence of Non-B Non-C Hepatocellular Carcinoma after Curative Treatment. Cancers, 2021, 13, 1542.	1.7	9
6	Proposal of Stroop test cutâ€off values as screening for neuropsychological impairments in cirrhosis: A Japanese multicenter study. Hepatology Research, 2021, 51, 674-681.	1.8	11
7	Usefulness of the Stroop Test in Diagnosing Minimal Hepatic Encephalopathy and Predicting Overt Hepatic Encephalopathy. Hepatology Communications, 2021, 5, 1518-1526.	2.0	10
8	Nutritional assessment tool for predicting sarcopenia in chronic liver disease. JCSM Rapid Communications, 2021, 4, 150-158.	0.6	2
9	Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan. Journal of Clinical Medicine, 2021, 10, 3448.	1.0	10
10	Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020. Journal of Gastroenterology, 2021, 56, 928-937.	2.3	7
11	Higher Accumulation of Visceral Adipose Tissue Is an Independent Risk Factor for Hepatocellular Carcinoma among Viral Hepatitis Patients with Non-Cirrhotic Livers. Cancers, 2021, 13, 5980.	1.7	1
12	Effect of l-carnitine supplementation on muscle cramps induced by stroke: A case report. Nutrition, 2020, 71, 110638.	1.1	5
13	Response to letter to the editor regarding: "Effect of l-carnitine supplementation on muscle cramps induced by stroke: A case report― Nutrition, 2020, 75-76, 110800.	1.1	Ο
14	Usefulness of Carnitine Supplementation for the Complications of Liver Cirrhosis. Nutrients, 2020, 12, 1915.	1.7	33
15	Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma. Cancers, 2020, 12, 1795.	1.7	15
16	Sustained virological response by direct‑acting antivirals reduces the recurrence risk of hepatitis C‑related hepatocellular carcinoma after curative treatment. Molecular and Clinical Oncology, 2020, 12, 111-116.	0.4	16
17	Development of diffuse large B‑cell lymphoma after sofosbuvir‑ledipasvir treatment for chronic hepatitis C: A case report and literature review. Molecular and Clinical Oncology, 2020, 13, 1.	0.4	8
18	Reduced handgrip strength is predictive of poor survival among patients with liver cirrhosis: A sexâ€stratified analysis. Hepatology Research, 2019, 49, 1414-1426.	1.8	51

Tatsunori Hanai

#	Article	IF	CITATIONS
19	Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers, 2019, 11, 1206.	1.7	38
20	Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment. International Journal of Molecular Sciences, 2019, 20, 605.	1.8	18
21	Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity scoreâ€matching analysis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1809-1816.	1.4	17
22	Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis. Hepatology Research, 2019, 49, 82-95.	1.8	31
23	Prevalence of Sarcopenia and Its Relationship with Nutritional State and Quality of Life in Patients with Digestive Diseases. Journal of Nutritional Science and Vitaminology, 2018, 64, 445-453.	0.2	22
24	Increased visceral fat volume raises the risk for recurrence of hepatocellular carcinoma after curative treatment. Oncotarget, 2018, 9, 14058-14067.	0.8	15
25	Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatology Research, 2017, 47, 1359-1367.	1.8	78
26	Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in Loss of Skeletal Muscle Volume. Nutrients, 2017, 9, 1054.	1.7	44
27	Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatology Research, 2016, 46, 743-751.	1.8	138
28	Impact of serum glycosylated <i>Wisteria floribunda</i> agglutinin positive Macâ€2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatology Research, 2015, 45, 1083-1090.	1.8	35
29	Skeletal Muscle Depletion Predicts the Prognosis of Patients with Hepatocellular Carcinoma Treated with Sorafenib. International Journal of Molecular Sciences, 2015, 16, 9612-9624.	1.8	56
30	Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial. Hepatology Research, 2015, 45, 514-522.	1.8	18
31	Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition, 2015, 31, 193-199.	1.1	321
32	Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. Journal of Gastroenterology, 2015, 50, 323-332.	2.3	205
33	Impact of Serum Chemerin Levels on Liver Functional Reserves and Platelet Counts in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2014, 15, 11294-11306.	1.8	26
34	Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: Chemoprevention of hepatocellular carcinoma using acyclic retinoid and branchedâ€chain amino acids. Molecular Nutrition and Food Research, 2014, 58, 124-135.	1.5	8
35	Free fatty acid as a marker of energy malnutrition in liver cirrhosis. Hepatology Research, 2014, 44, 218-228.	1.8	28
36	Branched-Chain Amino Acids Prevent Hepatocarcinogenesis and Prolong Survival of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1012-1018.e1.	2.4	84

#	Article	IF	CITATIONS
37	Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test. Journal of Cancer Research and Clinical Oncology, 2013, 139, 845-852.	1.2	43
38	Nutritional status and quality of life in current patients with liver cirrhosis as assessed in 2007–2011. Hepatology Research, 2013, 43, 106-112.	1.8	63